Roche's Rozlytrek (entrectinib) Receives the US FDA Approval for ROS1-Positive Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors
Shots:
- The US FDA has granted approval to Rozlytrek for ROS1-positive m-NSCLC in adults and accelerated approval for solid tumors having NTRK gene fusion in adults & pediatric patients aged≥ 12yrs.
- The approvals are based on integrated analysis of P-II STARTRK-2- P-I STARTRK-1- P-I ALKA-372-001 and P-I/II STARTRK-NG study resulted in 78% ORR- 1.8-36.8+ mos. DoR in ROS1-positive- m-NSCLC patients and 57% ORR and 2.8 to 26.0+ mos. DoR in patients with NTRK gene fusion-positive- LA/m-solid tumors
- Rozlytrek (PO) is a first selective tyrosine kinase inhibitor targeting TRK A/B/C and ROS1 proteins- blocking ROS1 and NTRK kinase activity thus resulting in the death of cancer cells with ROS1 or NTRK gene fusions
Click here to read full press release/ article
Ref: Roche | Image: Roche
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com